These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 15254918)
1. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Whitehead A; Perdomo C; Pratt RD; Birks J; Wilcock GK; Evans JG Int J Geriatr Psychiatry; 2004 Jul; 19(7):624-33. PubMed ID: 15254918 [TBL] [Abstract][Full Text] [Related]
2. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Rogers SL; Doody RS; Mohs RC; Friedhoff LT Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436 [TBL] [Abstract][Full Text] [Related]
3. Donepezil for dementia due to Alzheimer's disease. Birks JS; Harvey RJ Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184 [TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603 [TBL] [Abstract][Full Text] [Related]
5. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470 [TBL] [Abstract][Full Text] [Related]
6. Donepezil for mild and moderate Alzheimer's disease. Birks JS; Melzer D; Beppu H Cochrane Database Syst Rev; 2000; (4):CD001190. PubMed ID: 11034704 [TBL] [Abstract][Full Text] [Related]
7. Donepezil for dementia due to Alzheimer's disease. Birks J; Harvey RJ Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430 [TBL] [Abstract][Full Text] [Related]
8. Donepezil for dementia due to Alzheimer's disease. Birks JS; Harvey R Cochrane Database Syst Rev; 2003; (3):CD001190. PubMed ID: 12917900 [TBL] [Abstract][Full Text] [Related]
9. Donepezil for mild and moderate Alzheimer's disease. Birks J S; Melzer D Cochrane Database Syst Rev; 2000; (2):CD001190. PubMed ID: 10796620 [TBL] [Abstract][Full Text] [Related]
10. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Rogers SL Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673 [TBL] [Abstract][Full Text] [Related]
12. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421 [TBL] [Abstract][Full Text] [Related]
13. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453 [TBL] [Abstract][Full Text] [Related]
14. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278 [TBL] [Abstract][Full Text] [Related]
15. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895 [TBL] [Abstract][Full Text] [Related]
16. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405 [TBL] [Abstract][Full Text] [Related]
17. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Maher-Edwards G; Dixon R; Hunter J; Gold M; Hopton G; Jacobs G; Hunter J; Williams P Int J Geriatr Psychiatry; 2011 May; 26(5):536-44. PubMed ID: 20872778 [TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R; Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043 [TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Rogers SL; Friedhoff LT Eur Neuropsychopharmacol; 1998 Feb; 8(1):67-75. PubMed ID: 9452942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]